On April 16, 2025, Glycomine, a biotechnology company focused on developing transformative new therapies for orphan diseases, announced a $115 million Series C financing round led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. Wilson Sonsini Goodrich & Rosati advised Glycomine on the transaction.

Glycomine's GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation. Funds from the financing will support the advancement of GLM101 into a Phase 2b safety and efficacy study.

The Wilson Sonsini team that advised Glycomine on the transaction was led by Jennifer Knapp, Priyanka Nawathe, and Andrew Savage.

For more information, please see Glycomine's news release. Additional coverage can be found on Fierce Biotech and Biospace.